Repatha and Diphenhydramine Interaction: What Patients and Clinicians Need to Know

How Evolocumab (Repatha) Is Processed in the Body

Evolocumab is a fully human IgG2 monoclonal antibody. Its elimination route is entirely different from small-molecule drugs like statins or antihistamines.

Monoclonal antibodies are not metabolized by hepatic CYP450 enzymes. They are not substrates, inducers, or inhibitors of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or P-glycoprotein. Instead, evolocumab binds PCSK9 (proprotein convertase subtilisin/kexin type 9) in plasma, forming a drug-target complex that undergoes receptor-mediated endocytosis and subsequent lysosomal proteolytic catabolism into amino acids and small peptides, which are recycled or excreted renally.

The FDA prescribing information for evolocumab confirms this explicitly: "Evolocumab, as a monoclonal antibody, is not expected to be metabolized by CYP enzymes or to interact with drug transporters." [1]

Why Metabolic Pathway Matters for DDI Risk

Drug-drug interaction (DDI) risk between two agents depends heavily on whether they share the same metabolic enzymes or transport proteins. When pathways do not overlap, the pharmacokinetic DDI risk is essentially zero. Evolocumab and diphenhydramine share no metabolic pathway.

This is a meaningful distinction. Many patients on Repatha also take statins, fibrates, niacin, or antihypertensives, and those combinations must be evaluated carefully. Diphenhydramine does not belong to that list of pharmacokinetically problematic co-medications.

Bioavailability and Distribution Differences

Evolocumab is administered subcutaneously at 140 mg every two weeks or 420 mg once monthly. Peak plasma concentrations occur three to four days after injection. The drug distributes primarily in the vascular compartment, with a relatively small volume of distribution (approximately 3.3 L) consistent with a large-molecule biologic. Diphenhydramine, by contrast, is an oral small molecule with rapid gastrointestinal absorption, high lipophilicity, and a large volume of distribution (approximately 3 to 8 L/kg), enabling broad tissue penetration including the central nervous system.

These pharmacokinetic profiles do not intersect.

How Diphenhydramine Is Metabolized

Diphenhydramine is primarily metabolized by CYP2D6 via N-demethylation, with CYP1A2 and CYP2C9 playing minor secondary roles. [2] It also inhibits CYP2D6 at therapeutic doses, which can raise plasma concentrations of co-administered CYP2D6 substrates such as metoprolol, codeine, and certain antidepressants.

Anticholinergic Properties

Diphenhydramine is classified as a high-anticholinergic-burden drug by the Anticholinergic Cognitive Burden (ACB) scale, scoring a 3 out of 3. [3] This means it blocks muscarinic acetylcholine receptors, producing effects including dry mouth, urinary retention, constipation, tachycardia, blurred vision, and cognitive impairment.

In patients with established ASCVD, the cardiovascular subset of these effects deserves attention. Diphenhydramine-induced tachycardia may worsen myocardial oxygen demand in patients with coronary artery disease. This risk is independent of any interaction with evolocumab.

CNS Sedation Profile

Diphenhydramine crosses the blood-brain barrier readily due to its lipophilicity. Sedation typically begins within 15 to 30 minutes of an oral dose and may persist four to six hours. In older adults, this sedation can be disproportionate, contributing to falls, confusion, and impaired driving. The American Geriatrics Society Beers Criteria designate diphenhydramine as a potentially inappropriate medication for adults 65 years and older. [4]

Evolocumab has no CNS activity. It does not cross the blood-brain barrier. There is no pharmacodynamic basis for additive sedation between these two drugs.

Direct Evidence on the Evolocumab-Diphenhydramine Combination

No published randomized controlled trial, pharmacokinetic study, or case series has specifically examined the co-administration of evolocumab and diphenhydramine. This absence of dedicated interaction data is itself informative given the mechanistic clarity: because evolocumab bypasses all CYP and transporter-based pathways, a pharmacokinetic interaction study would be expected to show a null result.

Major DDI databases, including Lexicomp and Drugs.com, do not flag a clinically significant interaction between evolocumab and diphenhydramine as of the current review date. The FDA's drug interaction labeling for Repatha does not list diphenhydramine or any first-generation antihistamine as a co-medication of concern. [1]

The HealthRX Clinical Review Team developed the following decision framework for clinicians managing patients who ask about this specific combination:

HealthRX Evolocumab + Diphenhydramine Clinical Decision Framework

1. Confirm indication for diphenhydramine. Is it for acute allergic reaction, insomnia, or motion sickness? Each indication has alternatives with fewer anticholinergic risks (cetirizine or loratadine for allergy; melatonin or doxylamine with counseling for short-term insomnia).
2. Assess cardiovascular risk context. Patients on evolocumab typically have high or very-high ASCVD risk. Diphenhydramine-induced tachycardia may be clinically relevant in this population even without a drug interaction.
3. Screen for CYP2D6 substrate co-medications. Diphenhydramine inhibits CYP2D6. If the patient also takes metoprolol, carvedilol, or a tricyclic antidepressant, a true DDI exists between diphenhydramine and those drugs, not with evolocumab.
4. Apply Beers Criteria if patient is 65 or older. Prefer a second-generation antihistamine unless a specific clinical justification exists for diphenhydramine.
5. No dose adjustment of evolocumab is needed based on diphenhydramine co-administration.

The FOURIER Trial: What It Tells Us About Evolocumab's Safety Profile

The FOURIER trial (N=27,564) is the largest outcomes study for evolocumab. Published in the New England Journal of Medicine in 2017, it randomized patients with established atherosclerotic cardiovascular disease and LDL-C of 70 mg/dL or higher despite optimized statin therapy to evolocumab or placebo. Evolocumab reduced LDL-C by 59% from baseline (median on-treatment LDL-C: 30 mg/dL vs. 92 mg/dL placebo, P<0.001). The primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization was reduced by 15% (HR 0.85; 95% CI 0.79-0.92; P<0.001). [5]

What FOURIER Revealed About Drug Interactions

The FOURIER safety analysis did not identify any clinically significant drug interaction signals with antihistamines or CNS-active agents in the background medication list. The adverse event profile of evolocumab in FOURIER was notably clean: injection-site reactions occurred in 2.1% of participants, and rates of serious adverse events were similar between evolocumab and placebo arms.

The drug's consistent safety profile across a diverse patient population taking multiple background medications (statins, ACE inhibitors, beta-blockers, aspirin, and others) reinforces the mechanistic expectation that evolocumab does not produce pharmacokinetic interactions with drugs that use hepatic metabolic pathways.

Injection-Site Reactions and Diphenhydramine: A Nuanced Clinical Point

One scenario where diphenhydramine may be co-used with evolocumab is management of injection-site reactions. Mild local reactions, redness, bruising, or pruritus at the subcutaneous injection site, are reported in roughly 2% of evolocumab users based on the FOURIER data. Some patients or clinicians may consider an oral antihistamine to manage pruritus.

Topical or oral antihistamines are sometimes used for this purpose. If diphenhydramine is chosen for injection-site pruritus, the interaction risk remains low based on mechanism. A non-sedating alternative such as cetirizine 10 mg or loratadine 10 mg would provide equivalent antipruritic effect with a substantially better tolerability profile, particularly in older adults driving or operating machinery.

Patient Population Context: Who Takes Repatha?

Evolocumab is approved for adults with:

• Heterozygous familial hypercholesterolemia (HeFH)
• Homozygous familial hypercholesterolemia (HoFH)
• Established clinical ASCVD requiring additional LDL-C lowering beyond maximally tolerated statin therapy [1]

The typical Repatha patient is middle-aged to older, often with multiple cardiovascular comorbidities, and is already on a polypharmacy regimen. That context makes diphenhydramine's own risk profile the more clinically pressing consideration, not the theoretical drug interaction.

Age-Related Considerations

In patients 65 or older, diphenhydramine's anticholinergic and sedating effects are amplified. A prospective cohort analysis published in JAMA Internal Medicine found that higher cumulative anticholinergic medication exposure was associated with a 54% increased risk of dementia over a 10-year follow-up period (adjusted HR 1.54; 95% CI 1.21-1.96). [6] Whether this association reflects causation remains debated, but many clinicians now aim to minimize anticholinergic burden in older adults regardless of concurrent medications.

Patients on evolocumab who are 65 or older and reach for diphenhydramine for sleep or allergy symptoms deserve counseling about these risks as an independent clinical matter.

Patients With Familial Hypercholesterolemia

Patients with HeFH or HoFH often begin evolocumab at younger ages and may take it for decades. In younger patients, diphenhydramine's anticholinergic burden is less of a long-term concern, but its sedating properties remain relevant for occupational safety, driving, and academic or professional performance.

Monitoring Parameters When Both Drugs Are Used

When a patient on evolocumab needs diphenhydramine for any indication, the monitoring plan does not change from standard evolocumab follow-up.

Lipid Panel Monitoring

The Repatha prescribing information recommends a fasting lipid panel four to eight weeks after initiating therapy or adjusting dose, then periodically thereafter. [1] Diphenhydramine does not affect lipid metabolism and will not alter LDL-C, HDL-C, triglycerides, or total cholesterol. No additional lipid monitoring is triggered by co-administration.

Cardiovascular Parameters

If diphenhydramine is taken at standard doses (25 to 50 mg orally), transient heart rate elevation is possible. In patients with known coronary artery disease or arrhythmia history, clinicians should advise patients to report palpitations, chest discomfort, or unusual fatigue. This is a diphenhydramine-specific precaution, not a Repatha-specific one.

What to Watch for With Diphenhydramine

Standard diphenhydramine monitoring points, relevant regardless of evolocumab co-administration, include:

• Urinary retention, especially in men with benign prostatic hyperplasia
• Excessive sedation or morning grogginess with bedtime dosing
• Confusion or delirium in older adults, even after a single dose
• Dry mouth and constipation with repeated use
• Heart rate changes in patients with underlying arrhythmia or coronary disease

Patient Counseling Points

Patients who ask their pharmacist or physician about taking Benadryl while on Repatha can be reassured that no pharmacokinetic interaction exists. The conversation should then shift to the more clinically relevant concerns.

Key Messages for Patients

Repatha will not change how diphenhydramine works in your body. Repatha is a biologic that works by blocking a protein in the blood; it has no effect on liver enzymes that process antihistamines.

Diphenhydramine will not change how Repatha works. Your cholesterol-lowering effect from Repatha will not be reduced or increased by taking Benadryl.

Diphenhydramine itself carries risks that matter for your heart health. It can raise heart rate and cause significant drowsiness. If you have coronary artery disease or heart failure, talk to your doctor before using it regularly.

Safer alternatives exist for most indications. For allergies, cetirizine (Zyrtec) or loratadine (Claritin) work as well without the sedation and anticholinergic effects. For short-term insomnia, melatonin or behavioral strategies are preferred.

Do not use diphenhydramine long-term for sleep. The FDA does not approve any antihistamine for chronic insomnia. Tolerance to its sleep-inducing effect develops within a few nights.

Evolocumab's Broader Drug Interaction Profile

Because clinicians often encounter this question in the broader context of "what does interact with Repatha," a brief overview is warranted.

No CYP-Based Interactions

Evolocumab does not interact with statins (atorvastatin, rosuvastatin, simvastatin), ezetimibe, fibrates, or any other lipid-lowering agent through CYP pathways. The FOURIER trial included patients on high-intensity statins in the vast majority of the enrolled population, and no pharmacokinetic interference was detected.

Inclisiran Combination

The combination of evolocumab with inclisiran (an siRNA targeting PCSK9 mRNA) is under investigation. This is a pharmacodynamic overlap, not a pharmacokinetic interaction, and is not relevant to antihistamine co-administration.

Alirocumab (Praluent) Parallel

Alirocumab, the other approved PCSK9 inhibitor, shares the same monoclonal antibody elimination pathway. Interaction data for alirocumab with diphenhydramine is likewise absent from the literature because the same mechanistic logic applies: no CYP overlap, no transporter overlap, no expected DDI.

Summary of Clinical Bottom Line

No clinically significant interaction exists between evolocumab (Repatha) and diphenhydramine. The absence of shared metabolic enzymes or transport proteins eliminates pharmacokinetic DDI risk. Pharmacodynamic overlap (additive sedation, additive cardiovascular effects) is also absent because evolocumab has no CNS or cardiac receptor activity.

The clinical conversation for patients who ask about this combination should pivot quickly to the independent risk profile of diphenhydramine in the cardiovascular patient: its anticholinergic burden, its potential to raise heart rate, and the availability of safer alternatives for allergy relief and sleep support.

For patients 65 years or older on evolocumab who want an antihistamine, cetirizine 10 mg or loratadine 10 mg once daily is a better choice than diphenhydramine based on Beers Criteria guidance and the anticholinergic burden data from Coupland et al. (JAMA Internal Medicine, 2019).